Stelfonta Inj

Tigilanol tiglate injectable for intratumoral treatment of mast cell tumors in dogs. Tigilanol tiglate (EBC-46) intratumoral injectable antineoplastic. Mechanism: tigilanol tiglate activates protein kinase C (PKC) isoforms PKCδ and PKCε → induces tumor cell apoptosis and necrosis; also disrupts intratumoral blood vessels → hemorrhagic necrosis of tumor mass. FDA-approved for non-metastatic cutaneous/subcutaneous MCTs in dogs. Key information Tigilanol tiglate — equine intratumoral injection for mast cell tumors/SCC. Wear gloves and eye protection. Contains vesicant — avoid skin contact. Single-use. Injection site inflammation expected.

Intratumoral injection (by veterinary staff): draw up into syringe; inject into tumor using multiple small-volume injections distributed through the tumor mass. Aseptic technique. Single treatment per session; may repeat in 4–6 weeks. Store refrigerated (2–8°C); do not freeze. If a dose is missed This medication is administered by a veterinarian or veterinary staff in a clinical setting. Missed doses are managed by your veterinary team — contact your veterinarian to reschedule.

Local: pain, erythema, swelling, ulceration, necrosis at injection site (expected treatment effect — tumor destruction). Systemic: lethargy, anorexia, pyrexia (transient). GI: vomiting, diarrhea. Wound at treatment site requires care. Anaphylaxis (rare).

For animals Dogs only — intratumoral injection only; not for IV or peritumoral administration. Confirm MCT diagnosis histologically before treatment. Avoid in MCTs with metastatic disease. Local necrosis/wound care required post-treatment. Not approved for use in food-producing animals. For people handling this medication Wear gloves when handling. Wash hands thoroughly with soap and water after handling. Cytotoxic antineoplastic — wear gloves. Keep out of reach of children. Pregnant women and women of childbearing age should avoid contact. Administered by veterinary staff. Avoid contact with injection site exudate.

Contact your veterinarian immediately. Tigilanol tiglate is a vesicant administered by veterinary staff. Overdose causes severe local tissue destruction.